This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SIRT6 / NAD-dependent protein deacylase sirtuin-6 · IHC design guide
Design Immunohistochemistry for SIRT6
Plan SIRT6 chromogenic IHC in paraffin sections around the expected nuclear staining pattern (HPA tissue IHC). This guide covers fixation, antibody use, controls and scoring, with attention to the broad tissue distribution (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SIRT6 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear in tissue (HPA tissue IHC); ER fraction (UniProt) | |
| Staining pattern | Ubiquitous nuclear staining across cell types (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PB9357) | |
| Caveat | Widespread nuclear staining limits negative tissue controls (HPA tissue IHC) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | 2 isoforms; epitope differences unspecified (UniProt) |
Section 1
Recommended SIRT6 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with a published SIRT6 staining protocol for cardiac paraffin sections (PMC11187832).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PB9357); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SIRT6, 0.5-1μg/ml (datasheet PB9357) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SIRT6-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page antigen-retrieval rule); the published protocol specifies heat retrieval without conditions (PMC11187832).
Section 2
What Is the Expected SIRT6 Staining Pattern?
SIRT6 is predominantly nuclear, with a smaller endoplasmic reticulum fraction; it has no transmembrane segment (UniProt Q8N6T7). Expect nuclear staining across many cell types, including glandular, hematopoietic, epithelial and neuronal cells reported as High by HPA (HPA: tissue IHC). HPA describes the tissue pattern as ubiquitous nuclear expression and rates its reliability Supported, with medium consistency between staining and RNA data (HPA: tissue IHC).
| Clear nuclear chromogen in an HPA-listed cell population, with nuclei distinguishable from surrounding tissue. | This fits the predominant nuclear location (UniProt Q8N6T7) and HPA's ubiquitous nuclear IHC profile (HPA: tissue IHC). Judge intensity against cells on the same slide and a known-positive section; HPA's High category does not specify a chromogen shade or require every cell to stain equally (HPA: tissue IHC; general IHC practice). |
| Cytoplasmic staining dominates while nuclei are faint or unstained. | A dominant cytoplasmic pattern conflicts with the expected predominant nuclear signal (UniProt Q8N6T7; HPA: tissue IHC). Review specificity and detection controls before accepting it as SIRT6. Do not treat every extranuclear signal as false: UniProt reports an endoplasmic reticulum fraction, and HPA reports uncertain vesicular localization in ICC-IF (UniProt Q8N6T7; HPA: subcellular). |
| Staining appears chiefly outside an HPA-listed High population in a tested tissue. | For example, HPA reports High staining in adrenal glandular cells and bone marrow hematopoietic cells (HPA: tissue IHC). If those populations are negative while other cells stain strongly, check tissue identification and antibody or detection specificity (general IHC practice). HPA also describes broad expression, so an unlisted stained cell type alone does not establish cross-reactivity (HPA: tissue IHC). |
| A diffuse chromogen haze obscures nuclear boundaries throughout the section. | The expected distribution is nuclear (HPA: tissue IHC; UniProt Q8N6T7). Haze that also appears in a primary-antibody omission control points toward background from the detection workflow; review blocking, washes and endogenous detection activity (general IHC practice). Haze by itself cannot establish a SIRT6-specific tissue pattern. |
| No nuclear signal appears in a section containing an HPA-listed High population. | An absent result in, for example, bronchial respiratory epithelial or cerebral cortical neuronal cells conflicts with their reported High IHC levels (HPA: tissue IHC). First verify the control tissue and staining run, then review antibody conditions and detection reagents (general IHC practice). HPA reports medium staining-to-RNA consistency, so one negative result does not resolve target absence (HPA: tissue IHC). |
💡Expected SIRT6 appearanceCall the IHC result positive when nuclei are clearly stained in appropriate cells, with conspicuous signal in an HPA-listed High population; broad nonnuclear haze or dominant cytoplasmic staining warrants a specificity check (HPA: tissue IHC; UniProt Q8N6T7; general IHC practice).
| Compartment | Predominant nuclear localization sets the main scoring compartment (UniProt Q8N6T7; HPA: tissue IHC). UniProt also reports association with pericentric and telomeric heterochromatin and a smaller endoplasmic reticulum fraction; routine chromogenic IHC need not resolve those finer structures (UniProt Q8N6T7; general IHC practice). |
| Tissue reference | HPA calls the tissue pattern ubiquitous nuclear expression and RNA specificity Low tissue specificity (HPA: tissue IHC). Its listed High examples span glandular, hematopoietic, respiratory epithelial and neuronal populations (HPA: tissue IHC). The supplied HPA record lists no negative or low IHC tissues, so it offers no validated negative tissue comparator (HPA: tissue IHC). |
| Antibody evidence | HPA071776 has Supported IHC status; HPA049729 has no IHC status in the supplied antibody record (HPA: antibodies). The overall tissue reliability is Supported with medium staining-to-RNA consistency (HPA: tissue IHC). Interpret a discrepant section with controls rather than treating antibody status as proof that every stained cell is specific (general IHC practice). |
| Isoforms and epitope | UniProt lists two isoforms and a deacetylase sirtuin-type domain at residues 27–272 (UniProt Q8N6T7). The supplied evidence does not locate the IHC antibody's epitope or establish isoform-specific staining. Report what the assay shows without assigning a nuclear or extranuclear signal to one isoform. |
| Processing and modifications | UniProt lists no signal peptide, propeptide, transmembrane segment or glycosylation site, and records modified residues (UniProt Q8N6T7). These annotations do not show that a modification changes IHC staining. Target-specific fixation sensitivity and epitope retrieval requirements are unreported in the supplied evidence; optimize retrieval using assay controls (general IHC practice). |
| IF/ICC: Where should signal appear? | Mainly in the nucleoplasm: HPA rates that ICC-IF location Supported (HPA: subcellular). HPA also reports vesicles with Uncertain status, while UniProt describes predominantly nuclear SIRT6 and an endoplasmic reticulum fraction (HPA: subcellular; UniProt Q8N6T7). Treat vesicular signal cautiously and use the separate IF/ICC guide for that assay. |
| Situation | Likely cause | Next action |
|---|---|---|
| An HPA-listed High control population has no nuclear chromogen. | The run, antibody conditions or detection may have failed; the supplied sources do not identify a SIRT6-specific fixation cause (HPA: tissue IHC; general IHC practice). | Confirm the section contains the intended HPA-listed cell population, inspect run controls, then check primary antibody, antigen retrieval and detection conditions within the assay's validated workflow (HPA: tissue IHC; general IHC practice). |
| Cytoplasmic staining overwhelms a weak or absent nuclear signal. | The compartment pattern disagrees with predominant nuclear localization, though a smaller extranuclear fraction is reported (UniProt Q8N6T7; HPA: tissue IHC). | Compare a known-positive section and primary-antibody omission control, and assess whether the signal follows cell boundaries or diffuse background (general IHC practice). Require convincing nuclear staining before scoring the expected IHC pattern (UniProt Q8N6T7; HPA: tissue IHC). |
| Strong staining appears in an unexpected population while the listed High population is unstained. | Possible tissue misidentification, cross-reactivity or endogenous detection activity; staining outside an HPA-listed population alone is inconclusive because expression is broad (HPA: tissue IHC; general IHC practice). | Recheck cell identity and the HPA-listed population, then compare omission and detection controls (HPA: tissue IHC; general IHC practice). Describe the observed distribution if controls pass; do not claim the unexpected cells are SIRT6-negative without supporting evidence. |
| Diffuse staining persists across nuclei, cytoplasm and tissue spaces. | Background from detection, inadequate blocking or insufficient washing can obscure compartment assignment (general IHC practice). Such a field cannot reliably demonstrate HPA's nuclear pattern (HPA: tissue IHC). | Inspect a primary-antibody omission control and the slide's tissue-free areas, then adjust blocking, washes or chromogen development as indicated by the controls (general IHC practice). Rescore only where nuclear boundaries and cell identity are clear. |
| Nuclear staining is present but much weaker than expected in an HPA-listed High tissue. | HPA's High level is a reported staining category, not a fixed chromogen intensity standard; its overall tissue reliability is Supported with medium staining-to-RNA consistency (HPA: tissue IHC). Run conditions can also affect visible contrast (general IHC practice). | Compare the same cell population across the current run's positive controls and review retrieval, antibody dilution and development records (general IHC practice). Record weak nuclear staining as observed rather than converting it to an HPA-level claim. |
Experiment evidence
IHC & IF images showing SIRT6 staining
PB9357 · IHCAnti-SIRT6Picoband antibody, PB9357, IHC(P) IHC(P): Mouse Cardiac Muscle Tissue
PB9357 · IHCAnti-SIRT6Picoband antibody, PB9357, IHC(P) IHC(P): Human Mammary Cancer Tissue
A00611-3 · IFIF analysis of SIRT6 using anti-SIRT6 antibody (A00611-3) and anti-Beta Tubulin antibody (M01857-3). SIRT6 was detected in immunocytochemica
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000077463-SIRT6/tissue/cerebral+cortex#imid_19066863
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000077463-SIRT6/tissue/colon#imid_19066789
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000077463-SIRT6/tissue/liver#imid_19066774
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000077463-SIRT6/tissue/kidney#imid_19066783
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA049729; green = SIRT6, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA049729; green = SIRT6, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SIRT6 IHC & IF
🧪Run appendix first and assess nuclear staining in glandular cells (HPA: High in appendix glandular cells; UniProt Q8N6T7: predominantly nuclear). HPA detects SIRT6 in all 45 scored tissues, so there is no HPA-supported negative tissue; use no-primary and isotype controls, and treat any counterstained cells lacking nuclear signal on the positive slide as internal background references without assuming a particular cell type is SIRT6-negative (HPA: no negative tissue rows).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: SIRT6 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SIRT6 in A-431, MCF-7, U2OS, HaCaT, SH-SY5Y, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a control antibody matched to the primary antibody’s host species and class or isotype; use SIRT6 knockout material as a biological specificity control where available (standard IHC practice). For chromogenic appendix IHC, quench endogenous peroxidase and inspect inflammatory cells for residual peroxidase signal (standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence; the PB9357 tissue-IHC caption does not state a fixative (selected PB9357 caption). Antigen retrieval may need optimization for paraffin sections, but a SIRT6-specific retrieval requirement is unreported, and the evidence does not establish whether frozen sections or IF are easier (standard IHC practice; supplied evidence). In appendix, inflammatory-cell peroxidase can complicate chromogenic interpretation, so judge glandular nuclear staining against the control slides (HPA: High in appendix glandular cells; standard IHC practice).
HPA tissue IHC evidence for SIRT6
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: SIRT6 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced SIRT6 IHC Tips
Troubleshoot SIRT6 staining by checking nuclear localisation, antibody specificity and section handling before comparing signal across samples.
How should I retrieve SIRT6 antigen when nuclear staining is weak?
Start with Tris-EDTA pH 9.0 heat-induced antigen retrieval at 95–98 °C for 20 min (page retrieval setting: nuclear antigen). Allow sections to cool consistently, then compare nuclear signal and tissue morphology against a section processed with the same detection reagents (standard IHC practice). If staining remains weak, test citrate pH 6.0 on an adjacent section as a fallback, changing only the retrieval condition (standard IHC practice). Score whether the change improves nuclear staining without increasing diffuse tissue colour or damaging morphology; predominantly nuclear staining is expected for SIRT6 (UniProt Q8N6T7; HPA tissue IHC). Keep retrieval conditions identical across sections intended for quantitative comparison (standard IHC practice).
Could fixation explain weak or uneven SIRT6 staining in paraffin sections?
Target-specific fixation sensitivity for SIRT6 is unknown from the supplied evidence; the PB9357 mouse cardiac muscle IHC(P) caption does not state a fixative (PB9357 tissue-IHC caption). Record each specimen’s fixative and fixation duration, and compare sections with documented, similar processing histories before attributing a signal difference to SIRT6 abundance (standard IHC practice). Uneven fixation can alter morphology and antigen access, so inspect the stained section for regional variation alongside its counterstain (standard IHC practice). If processing histories differ, optimise retrieval and antibody conditions on representative sections, then apply one chosen workflow consistently to the study set (standard IHC practice).
How should I assess nuclear and extranuclear SIRT6 staining?
Assess nuclear staining first: tissue IHC reports ubiquitous nuclear expression, and the supported ICC/IF location is nucleoplasm (HPA tissue IHC; HPA subcellular). SIRT6 is also associated with heterochromatin and DNA damage sites, while a fraction has been reported at the endoplasmic reticulum (UniProt Q8N6T7). Thus, an extranuclear signal merits careful review, but the paraffin-section stain alone cannot establish which structure it occupies (UniProt Q8N6T7; standard IHC practice). Compare the signal with nuclear counterstain, morphology and an antibody-specific control before calling a new compartment (standard IHC practice). Report nuclear and extranuclear observations separately, including whether extranuclear colour is diffuse or confined to identifiable cells (standard IHC practice).
Can this stain distinguish SIRT6 isoforms or detect modified SIRT6?
SIRT6 has 2 annotated isoforms, but the supplied antibody evidence does not map its epitope or establish isoform selectivity (UniProt Q8N6T7; PB9357 tissue-IHC caption). The sirtuin-type deacetylase domain spans residues 27–272, and annotated modifications include Ser10, Lys33, Thr294 and Ser303 (UniProt Q8N6T7). Without epitope mapping, a change in chromogenic staining cannot distinguish altered protein abundance from altered epitope accessibility or modification (standard IHC interpretation). Check antibody documentation and, where isoform or modification specificity matters, use a separately validated assay for that question (standard IHC practice). Describe the result as SIRT6 immunoreactivity rather than an isoform-specific measurement (standard IHC interpretation).
How can I follow up SIRT6 IHC findings by multiplex IF?
For a separate IF/ICC experiment, pair SIRT6 with a validated marker of the cell population being assessed and a nuclear counterstain; HPA reports high nuclear staining in neuronal cells of the cerebral cortex, among other populations (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores after checking tissue autofluorescence, and assign the brighter channel to the weaker target signal if needed (standard IF practice). Permeabilise sufficiently to reach the nuclear epitope; SIRT6 is predominantly nuclear and has no annotated transmembrane segment (UniProt Q8N6T7; standard IF practice). Use single-colour and secondary-only controls to assess bleed-through and background (standard IF practice). Do not transfer a fixation choice from the PB9357 tissue-IHC caption, which does not report one (PB9357 tissue-IHC caption).
What should I check when SIRT6 DAB staining looks diffuse?
Compare the DAB pattern with the nuclear counterstain before increasing antibody concentration: the expected tissue pattern is predominantly nuclear (HPA tissue IHC). Include a no-primary control to expose detection-system colour, and check whether endogenous peroxidase blocking removes colour unrelated to antibody binding (standard chromogenic IHC practice). Inspect section edges, folds and poorly preserved areas separately, because local staining there can distort an apparent SIRT6 pattern (standard IHC practice). If nuclei remain faint while background rises, reassess retrieval, blocking, antibody concentration and wash stringency one variable at a time (standard IHC practice). Record exposure to chromogen consistently when comparing study sections (standard chromogenic IHC practice).
How should I quantify SIRT6 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue region before scoring, then quantify nuclear SIRT6 with an H-score or the percentage of positive nuclei using one threshold across the study (HPA tissue IHC; standard IHC practice). For spatial questions, report positive nuclei per mm² together with total nuclei per mm², so differences in cellularity are visible (standard IHC practice). Normalise positive counts to the number of evaluable nuclei in the same region, and exclude folds, edges and necrotic areas using preset rules (standard IHC practice). Keep retrieval, detection and image-acquisition settings consistent, and score representative fields without selecting them by staining intensity (standard IHC practice). Report nuclear and extranuclear signal separately if both are present (standard IHC practice).
When is a SIRT6-positive result convincing rather than artefactual?
A convincing result places signal in identifiable nuclei, consistent with the ubiquitous nuclear tissue profile and supported nucleoplasmic ICC/IF location (HPA tissue IHC; HPA subcellular). Check that positive cells match their morphology and that signal persists away from section edges, folds and necrotic regions (standard IHC practice). Treat exclusively diffuse cytoplasmic colour cautiously; an endoplasmic-reticulum fraction is reported, but chromogenic localisation alone cannot identify that fraction (UniProt Q8N6T7; standard IHC interpretation). A no-primary control helps reveal endogenous enzyme or detection background, while an independently validated antibody or orthogonal assay strengthens target assignment (standard IHC practice). Interpret staining intensity as immunoreactivity, not a direct measure of SIRT6 enzymatic activity (UniProt Q8N6T7; standard IHC interpretation).
Boster reagents
Best SIRT6 / NAD-dependent protein deacylase sirtuin-6 IHC Antibodies
IHC and IF data cover mouse cardiac muscle paraffin sections, human mammary cancer paraffin sections, and U2OS cells (PB9357 and A00611-3 image captions).
Real IHC data
Anti-SIRT6 Antibody ®
Cat # PB9357
Real IF data
Anti-SIRT6 Antibody ®
Cat # A00611-3
PB9357 has IHC(P) images of mouse cardiac muscle and human mammary cancer tissue (PB9357 image captions). A00611-3 has an IF image of U2OS cells and is listed for IF/ICC (A00611-3 image caption and catalog applications).
Which to pick: Choose PB9357 for tissue IHC: its mouse cardiac muscle image identifies a paraffin section, and its IHC listing covers human and mouse; the fixative is unreported (PB9357 image caption and catalog reactivity). Choose A00611-3 for human IF/ICC (A00611-3 catalog applications and reactivity). For IHC across human, mouse, and rat, consider the rabbit polyclonal A00611-2; its catalog lists all three species and IHC, but supplies no IHC image (A00611-2 catalog reactivity, dilution record, applications, and image list).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q8N6T7 (SIR6_HUMAN, NAD-dependent protein deacylase sirtuin-6).
- Human Protein Atlas. SIRT6 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. SIRT6 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to vesicles..
- Human Protein Atlas. SIRT6 antibody validation summary (2 antibodies).
- Protective Effects of SIRT6 Overexpression against DSS-Induced Colitis in Mice. Cells 2020 — PMC7348883.
- Sirt6 attenuates chondrocyte senescence and osteoarthritis progression. Nature communications 2022 — PMC9741608.
- Berberine ameliorates chronic intermittent hypoxia-induced cardiac remodelling by preserving mitochondrial function, role of SIRT6 signalling. Journal of cellular and molecular medicine 2024 — PMC11187832.
- Hepatic Sirt6 activation abrogates acute liver failure. Cell death & disease 2024 — PMC11035560.
- PubMed PMID:10873683 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SIRT6 (NAD-dependent protein deacylase sirtuin-6). Expected localisation Nuclear in tissue (HPA tissue IHC); ER fraction (UniProt). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: PB9357 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PB9357); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SIRT6, 0.5-1μg/ml (datasheet PB9357); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PB9357); Caveat: Widespread nuclear staining limits negative tissue controls (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope differences unspecified (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt Q8N6T7, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to…, Datasheet PB9357, PMC11187832. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SIRT6/immunohistochemistry-ihc-guide.